Sugi Predict

Sugi Predict / Compounds / SCHEMBL8939508

SCHEMBL8939508

SCHEMBL8939508

CC(C)(C)OC(=O)N[C@@H](Cc1c[nH]c2ccc(F)cc12)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 2/20 0.63
▸ ACE P12821 3/20 0.61
▸ CTSL P07711 2/20 0.56
▸ CTSS P25774 1/20 0.56
▸ CTSK P43235 1/20 0.56
▸ TACR1 P25103 2/20 0.55
▸ ITGB2 P05107 3/20 0.54
▸ ICAM1 P05362 3/20 0.54
▸ ITGAL P20701 3/20 0.54
▸ MAPT P10636 2/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ TP53 P04637 1/20 0.52
▸ ADAM17 P78536 1/20 0.51
▸ TSHR P16473 1/20 0.50
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ HTR2A P28223 1/20 0.49
▸ HTR2C P28335 1/20 0.49
▸ SSTR3 P32745 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31278511 1.00 SCN9A (0.63) SCN9AACECTSLCTSSCTSK
SCHEMBL23270828 1.00 SCN9A (0.63) SCN9AACECTSLCTSSCTSK
SCHEMBL11439689 0.92 SCN9A (0.68) SCN9AACECTSLCTSSCTSK
SCHEMBL3014096 0.92 SCN9A (0.68) SCN9AACECTSLCTSSCTSK
SCHEMBL31277956 0.91 TACR1 (0.61) SCN9AACECTSLCTSSCTSK
SCHEMBL25502042 0.91 TACR1 (0.61) SCN9AACECTSLCTSSCTSK
SCHEMBL4108869 0.88 ACE (0.62) SCN9AACECTSLCTSSCTSK
SCHEMBL8208133 0.88 MAPT (0.63) SCN9AACECTSLCTSSCTSK
SCHEMBL4112957 0.88 ACE (0.62) SCN9AACECTSLCTSSCTSK
SCHEMBL21292790 0.88 ACE (0.62) SCN9AACECTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577259-B2 PCSK9 antagonist compounds MERCK SHARP & DOHME LLC (US) 2026-03-17 — — US disclosed
US-11795196-B2 Mitochondria-targeting peptides STEALTH BIOTHERAPEUTICS INC. (US) 2023-10-24 — — US disclosed
EP-3810129-B1 PCSK9 ANTAGONIST BICYCLO-COMPOUNDS MERCK SHARP & DOHME LLC (US) 2023-08-16 — — EP disclosed
EP-3810129-B1 PCSK9 ANTAGONIST BICYCLO-COMPOUNDS MERCK SHARP & DOHME LLC (US) 2023-08-16 — — EP disclosed
US-20230165932-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-06-01 — — US disclosed
US-20230159592-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-05-25 — — US disclosed
US-20230144324-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-05-11 — — US disclosed
US-20230144324-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-05-11 — — US disclosed
US-20230144324-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-05-11 — — US disclosed
US-11306125-B2 PCSK9 antagonists bicyclo-compounds MERCK SHARP & DOHME CORP. (US) 2022-04-19 — — US disclosed
US-20210214395-A1 PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS MERCK SHARP & DOHME LLC 2021-07-15 — — US disclosed
US-20210214395-A1 PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS MERCK SHARP & DOHME LLC 2021-07-15 — — US disclosed
WO-2021127460-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2021-06-24 — — WO disclosed
EP-3810129-A1 PCSK9 ANTAGONIST BICYCLO-COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2021-04-28 — — EP disclosed
US-20210069288-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2021-03-11 — — US disclosed
EP-0563132-B1 TETRAPEPTIDE DERIVATIVES AND ANALOGUES BLACK JAMES FOUNDATION (GB) 1996-02-07 — — EP disclosed
US-5486597-A GASTRIN ANTAGONIST AS ANTISECRETORY AGENTS OF GASTRIC JUICE FOR STOMACH CANCER JAMES BLACK FOUNDATION LIMITED (GB) 1996-01-23 — — US disclosed
EP-0563132-A1 TETRAPEPTIDE DERIVATIVES AND ANALOGUES. BLACK JAMES FOUNDATION (GB) 1993-10-06 — — EP disclosed
WO-1992011284-A1 TETRAPEPTIDE DERIVATIVES AND ANALOGUES THE JAMES BLACK FOUNDATION LIMITED (GB) 1992-07-09 — — WO disclosed
US-4224199-A ANTIDIABETIC MEYERS CHESTER A 1980-09-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210214395-A1 PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS PCSK9, PCSK7, PCSK6 SCN9A 1912/4885ACE 169/4885CTSL 226/4885
US-20210069288-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 SCN9A 1255/4885ACE 55/4885CTSL 213/4885
US-20230165932-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 SCN9A 1255/4885ACE 55/4885CTSL 213/4885
US-20230159592-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 SCN9A 1424/4885ACE 188/4885CTSL 506/4885
US-11306125-B2 PCSK9 antagonists bicyclo-compounds PCSK9, PCSK7, PCSK6 SCN9A 1912/4885ACE 169/4885CTSL 226/4885
US-11795196-B2 Mitochondria-targeting peptides HSPE1, TFAM, TNNI3 SCN9A 3097/4885ACE 4361/4885CTSL 1359/4885
US-12577259-B2 PCSK9 antagonist compounds PCSK9, LDLR, PCSK6 SCN9A 1221/4885ACE 571/4885CTSL 455/4885
US-20230144324-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 SCN9A 1739/4885ACE 58/4885CTSL 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.